Citalopram: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
WanaraLima (bicara | kontrib) Dibuat dengan menerjemahkan halaman "User:Mr. Ibrahem/Citalopram" |
k Moving from Category:Fluoroarena to Category:Senyawa 4-fluorofenil using Cat-a-lot Tag: halaman dengan galat kutipan |
||
| (9 revisi perantara oleh 4 pengguna tidak ditampilkan) | |||
Baris 1:
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443526669
| image = Citalopram racemic.svg
| width = 190
| caption = (''R'')-(−)-citalopram (top),<br />(''S'')-(+)-citalopram (bottom)
| chirality = [[Racemic mixture]]
<!--Clinical data-->
'''Citaloprama''' adalah obat untuk mengatasi [[antidepresan]] golongan Selective Serotonin Reuptake Inhibitor (SSRI). <ref name="AHFS2018">{{Cite web|title=Citalopram Hydrobromide Monograph for Professionals |url=https://www.drugs.com/monograph/citalopram-hydrobromide.html |website=Drugs.com |publisher=AHFS |archive-date=23 December 2018 |archive-url=https://web.archive.org/web/20181223073739/https://www.drugs.com/monograph/citalopram-hydrobromide.html |url-status=live |access-date=23 December 2018}}</ref> Obat ini digunakan untuk mengatasi [[gangguan depresi mayor]], [[gangguan obsesif kompulsif]], gangguan panik, dan [[Gangguan kecemasan sosial|fobia sosial]] . <ref name="AHFS2018">{{cite web |title=Citalopram Hydrobromide Monograph for Professionals |url=https://www.drugs.com/monograph/citalopram-hydrobromide.html |website=Drugs.com |publisher=AHFS |accessdate=23 December 2018 |archive-date=23 December 2018 |archive-url=https://web.archive.org/web/20181223073739/https://www.drugs.com/monograph/citalopram-hydrobromide.html |url-status=live }}</ref> Untuk mendapatkan efek terapi antidepresan diperlukan waktu satu hingga empat minggu. <ref name="AHFS2018">{{cite web |title=Citalopram Hydrobromide Monograph for Professionals |url=https://www.drugs.com/monograph/citalopram-hydrobromide.html |website=Drugs.com |publisher=AHFS |accessdate=23 December 2018 |archive-date=23 December 2018 |archive-url=https://web.archive.org/web/20181223073739/https://www.drugs.com/monograph/citalopram-hydrobromide.html |url-status=live }}</ref> Rute pemberian obat melalui oral. <ref name="AHFS2018">{{cite web |title=Citalopram Hydrobromide Monograph for Professionals |url=https://www.drugs.com/monograph/citalopram-hydrobromide.html |website=Drugs.com |publisher=AHFS |accessdate=23 December 2018 |archive-date=23 December 2018 |archive-url=https://web.archive.org/web/20181223073739/https://www.drugs.com/monograph/citalopram-hydrobromide.html |url-status=live }}</ref>▼
| pronounce = {{IPAc-en|s|aɪ|ˈ|t|æ|l|ə|ˌ|p|r|æ|m|,_|s|ɪ|-}};{{refn|{{MerriamWebsterDictionary|Citalopram}}}}
| tradename = Celexa, Cipramil, others<ref name="Citalopram International" />
| Drugs.com = {{drugs.com|monograph|citalopram-hydrobromide}}
| MedlinePlus = a699001
| DailyMedID = Citalopram
| pregnancy_AU = C
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy" />
| routes_of_administration = [[Oral administration|oral]], [[Intravenous therapy|intravenous]]<ref name=intravenous>{{cite journal | vauthors = Kasper S, Müller-Spahn F | title = Intravenous antidepressant treatment: focus on citalopram | journal = European Archives of Psychiatry and Clinical Neuroscience | volume = 252 | issue = 3 | pages = 105–109 | date = June 2002 | pmid = 12192466 | doi = 10.1007/s00406-002-0363-8 | s2cid = 24991131 }}</ref><ref name=ivocd/><ref name=citalopramvsclomipramine/>
| class = [[Selective serotonin reuptake inhibitor]] (SSRI)<ref name=AHFS2018/>
| ATC_prefix = N06
| ATC_suffix = AB04
| ATC_supplemental =
| legal_AU = S4
| legal_BR = C1
| legal_BR_comment = <ref>{{cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref>
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_US_comment = <ref name="Celexa FDA label" />
<!--Pharmacokinetic data-->
| bioavailability = 80% <br/>peak at 4 h<ref name=AHFS2018/>
| protein_bound = <80%<ref name="Celexa FDA label">{{cite web | title=Celexa- citalopram tablet, film coated | website=DailyMed | date=15 August 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4259d9b1-de34-43a4-85a8-41dd214e9177 | access-date=28 October 2020}}</ref>
| metabolism = [[Liver]] ([[CYP3A4]] and [[CYP2C19]])
| metabolites = Desmethylcitalopram (DCT) and didesmethylcitalopram (DDCT)
| elimination_half-life = 35 h
| excretion = Mostly as unmetabolized citalopram, partly DCT and traces of DDCT in urine
<!-- Identifiers -->
| index2_label = as salt
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 59729-33-8
| PubChem = 2771
| IUPHAR_ligand = 7547
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00215
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2669
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0DHU5B8D6V
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07704
| KEGG2_Ref = {{keggcite|correct|kegg}}
| KEGG2 = D00822
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3723
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 549
<!--Chemical data-->
| IUPAC_name = (''RS'')-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
| C = 20
| H = 21
| F = 1
| N = 2
| O = 1
| SMILES = Fc1ccc(cc1)C3(OCc2cc(C#N)ccc23)CCCN(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WSEQXVZVJXJVFP-UHFFFAOYSA-N
}}
▲'''
Kejadian efek samping obat yang umum pada obat ini seperti rasa mual, insomnia, masalah seksual, gemetar, merasa lelah, dan berkeringat. <ref name="AHFS2018" /> Kejadian efek samping yang serius yakni potensi risiko [[bunuh diri]] jika digunakan pada individu usia di bawah 25 tahun, [[sindrom serotonin]], [[glaukoma]], dan [[Sindrom QT panjang|perpanjangan interval QT]] . <ref name="AHFS2018" /> Obat Ini tidak direkomendasikan untuk digunakan bersama golongan inhibitor MAO . <ref name="AHFS2018" /> Sindrom penghentian antidepresan dapat terjadi ketika dihentikan. <ref name="AHFS2018" /> Penggunaan obat ini pada ibu hamil berpotensi membahayakan bayi.<ref>{{Cite web|title=Citalopram (Celexa) Use During Pregnancy|url=https://www.drugs.com/pregnancy/citalopram.html|website=Drugs.com|archive-url=https://web.archive.org/web/20181223073744/https://www.drugs.com/pregnancy/citalopram.html|archive-date=23 December 2018|access-date=23 December 2018|url-status=live}}</ref>
== Referensi ==
[[Kategori:Obat yang dikembangkan oleh AbbVie]]
[[Kategori:
[[Kategori:Benzonitril]]
[[Kategori:Penghambat CYP2D6]]
[[Kategori:Senyawa dimetilamino]]
[[Kategori:Senyawa 4-fluorofenil]]
[[Kategori:Isobenzofuran]]
[[Kategori:Penghambat pengambilan kembali serotonin selektif]]
[[Kategori:Agonis sigma]]
<references />{{Farmasi-stub}}
| |||